Please login to the form below

Not currently logged in
Email:
Password:

Avita Medical appoints CEO

Dr Michael Perry joins from Novartis

Avita Medical has appointed Dr Michael Perry as its new chief executive officer at a time when the firm plans to submit its burn treatment ReCell to the FDA for review.

Perry has been a non-executive director for the Cambridge, UK-based regenerative medicine firm since February 2013 and previously served at Novartis in roles such as senior vice president and chief scientific officer, global business development and licensing, and chief scientific officer for its cell and gene therapy unit.

Prior to Novartis Perry was global head of R&D for the bioscience division at Baxter Healthcare, vice president of regulatory affairs for Sandoz Pharma, and president and CEO of cell and gene therapies for Novartis subsidiaries Systemix Inc. and Genetic Therapy Inc.

Lou Panaccio, chairman of Avita, said: “Mike’s expertise across the value chain in cell therapy along with his experience in business development, regulatory affairs and general management will be crucial to Avita’s future success.

“These fundamental attributes complemented by his US presence, will maximise Avita’s prospects as the company progresses through PMA submission, FDA review and preparation for large-scale product commercialisation.”

Perry succeeds Adam Kelliher after two years of service and will remain a consultant to the board of directors.

16th June 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

The new pharma marketing playbook
Learn about the 5 areas that must be in your pharma marketing playbook...
Pharma needs to evolve from customer-centricity to stakeholder-centricity
Customer-centricity and patient-centricity is no longer enough for pharma sales and marketing strategies as digital promises better customer experiences for all pharma stakeholders....
5 health behavioural factors to incorporate in your marketing
Achieve real health behaviour change by including these elements in your pharmaceutical marketing....

Infographics